Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 26, 2017
What is the competitive landscape for DAIICHI SANKYO, and when can generic versions of DAIICHI SANKYO drugs launch?
DAIICHI SANKYO has eleven approved drugs.| Patents: | 5 |
| Tradenames: | 9 |
| Ingredients: | 9 |
| NDAs: | 11 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
colesevelam hydrochloride | Powder for Oral Suspension | 1.875 g/Packet and 3.75 g/Packet | WELCHOL | 4/9/2010 |
colesevelam hydrochloride | Tablets | 625 mg | WELCHOL | 7/1/2009 |
cevimeline hydrochloride | Capsules | 30 mg | EVOXAC | 2/27/2009 |
amlodipine besylate and olmesartan medoxomil | Tablets | 10 mg/20 mg and 5 mg/40 mg | AZOR | 3/31/2008 |
amlodipine besylate and olmesartan medoxomil | Tablets | 5 mg/20 mg and 10 mg/40 mg | AZOR | 2/11/2008 |
olmesartan medoxomil and hydrochlorothiazide | Tablets | 20 mg/12.5 mg | BENICAR HCT | 5/11/2007 |
olmesartan medoxomil and hydrochlorothiazide | Tablets | 40 mg/12.5 mg and 40 mg/25 mL | BENICAR HCT | 2/15/2007 |
olmesartan medoxomil | Tablets | 5 mg, 20 mg and 40 mg | BENICAR | 4/25/2006 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5,646,171 | Angiotensin II antagonist 1-biphenylmethylimidazole compounds and their therapeutic use | ► Subscribe | |||||||||||||
| 8,377,428 | Low salt forms of polyallylamine | ► Subscribe | |||||||||||||
| 7,541,024 | Low salt forms of polyallylamine | ► Subscribe | |||||||||||||
| 7,342,014 | Diamine derivatives | ► Subscribe | |||||||||||||
| 7,261,880 | Methods of treating Syndrome X with aliphatic polyamines | ► Subscribe | |||||||||||||
| 8,267,452 | Product gripper | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia | 647887 | ► Subscribe | |||||||||||||
| Poland | 398653 | ► Subscribe | |||||||||||||
| Japan | 3461863 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 02085383 | ► Subscribe | |||||||||||||
| Denmark | 0545912 | ► Subscribe | |||||||||||||
| Ireland | 920540 | ► Subscribe | |||||||||||||
| European Patent Office | 2187873 | ► Subscribe | |||||||||||||
| Hungary | 9301600 | ► Subscribe | |||||||||||||
| Japan | H0578328 | ► Subscribe | |||||||||||||
| Luxembourg | 91330 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 00095 | Netherlands | ► Subscribe | PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419 | ||||||||||||
| 835 | Luxembourg | ► Subscribe | PRODUCT NAME: EDOXABAN, UN DE SES SELS, UN DE SES SOLVATES OU UN N-OXYDE DE CELUI-CI, EN PARTICULIER UN TOSYLATE D EDOXABAN. FIRST REGISTRATION: 20150619 | ||||||||||||
| 0760 | Netherlands | ► Subscribe | PRODUCT NAME: EDOBAXAN, EEN ZOUT DAARVAN, EEN SOLVAAT DAARVAAN OF EEN N-OXIDE DAARVAN, IN HET BIJZONDER EDOBAXAN TOSYLAAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 | ||||||||||||
| 2015000077 | Germany | ► Subscribe | PRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 | ||||||||||||
| 0503785/01 | Switzerland | ► Subscribe | FORMER OWNER: SANKYO COMPANY LIMITED, JP | ||||||||||||
| /2009 | Austria | ► Subscribe | PRODUCT NAME: KOMBINATION VON OLMESARTAN MEDOXOMIL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH AKZEPTABLEN SALZES, MIT AMLODIPINBESILAT; NAT. REGISTRATION NO/DATE: 1-27894, 1-27895, 1-27896 20081217; FIRST REGISTRATION: NL 100989, 100990, 100991 20080819 | ||||||||||||
| C0037 | France | ► Subscribe | PRODUCT NAME: OLMESARTAN MEDOXOMIL; NAT. REGISTRATION NO/DATE: NL28292 20030806; FIRST REGISTRATION: DE - 50202.00 20020813 | ||||||||||||
| 315 | Luxembourg | ► Subscribe | PRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE | ||||||||||||
| C0009 | Belgium | ► Subscribe | PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015 | ||||||||||||
| 00159 | Netherlands | ► Subscribe | PRODUCT NAME: COLESEVELAM, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/03/268/001 20040310 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,768 others who get our Drug Patent Expiration Alerts:
